S&P 500 Healthcare Sector SPDR (XLV)

Although Thermo Fisher Scientific has underperformed the broader market over the past 52 weeks, Wall Street analysts maintain a highly optimistic outlook about the stock’s prospects.

Despite DexCom’s weak performance relative to the broader market over the past year, Wall Street analysts remain bullish about the stock’s prospects.

Becton, Dickinson and Company has lagged behind the broader market over the past year, yet analysts remain somewhat optimistic about the stock’s prospects.

Solventum has lagged behind the broader market over the past year, and analysts remain somewhat optimistic about the stock’s prospects.

Though Hologic has outperformed the broader market over the past year, Wall Street analysts maintain a cautious outlook on the stock’s prospects.

Resilient stocks and ETFs offering steady demand and dividend yields may help investors weather further market turbulence without abandoning equity exposure.

Are Wall Street analysts bullish or bearish on DaVita’s stock after its fourth-quarter earnings?

Zoetis stock has underperformed the broader market over the past year, while analysts remain cautiously bullish about its prospects.

Cardinal Health has outperformed the broader market over the past year, and analysts remain highly optimistic about the stock’s prospects.

While Abbott Laboratories has underperformed the broader market over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.